Spectranetics releases final 1-year results for Stellarex drug-coated balloon

Spectranetics (NSDQ:SPNC) today released the final 1-year results from the Illumenate EU RCT study comparing treatment with its Stellarex drug-coated balloon to percutaneous transluminal angioplasty, touting a 24% higher rate of primary patency with the DCB. One-year results from the 328-patient trial were presented at the Amputation Prevention Symposium in Chicago this week. “The Stellarex DCB produced outstanding results in this rigorous trial, validating its earlier first-in-human and interim Illumenate global studies. These consistent, high quality outcomes are achieved with a low dose drug balloon, making this device especially compelling. Physicians now have a powerful tool to prevent restenosis and improve their patients’ quality of life,” study national principal investigator Dr. Henrik Schöder of Berlin’s Jewish Hospital said in a press release. Primary patency for patients treated with the Stellarex DCB was reported to be 89%, with patients treated with PTA at 65%, according to the study. Freedom from clinically-driven target lesion revascularization was 94.8% for the DCB group and 85.3% for those treated with PTA. “While results clearly show a highly significant gain compared to PTA, they favorably match the highest rates of primary patency with a low drug dose. It is very encouraging for us physicians to observe such a tremendous evolution in DCB technologies and appreciate how low-dose and highly stable coatings such as Stellarex can ac...
Source: Mass Device - Category: Medical Equipment Authors: Tags: Catheters Clinical Trials Vascular Spectranetics Corp. Source Type: news